ACN Accenture Plc Class A

Accenture Launches the Intelligent Patient Service Exchange to Help Life Sciences Companies Integrate Technology Solutions into Their Patient Services Programs

Accenture (NYSE:ACN) has launched the Intelligent Patient Service Exchange, a digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221005653/en/

Accenture Intelligent Patient Service Exchange: A digital marketplace of third-party technology solu ...

Accenture Intelligent Patient Service Exchange: A digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience. (Graphic: Business Wire)

The Intelligent Patient Service Exchange removes the time and cost needed to develop custom, digital patient-centric solutions by offering pre-built, plug-and-play technology connections that enable life sciences companies to integrate patient services more quickly and at a lower cost than previously possible. These include capabilities such as storing medical documents and streamlining physician assistants’ correspondence with patients and healthcare provider.

The Intelligent Patient Service Exchange is embedded into the Accenture Intelligent Patient Platform - a suite of integrated analytics-driven solutions that help life sciences companies design, deliver, measure and refine more precise support programs for patient segments.

“With the launch of the Intelligent Patient Service Exchange, our platform continues to be instrumental in helping life sciences companies use analytics and collaborative technologies to improve the patient experience and also work across the healthcare system,” said Tony Romito, managing director, Accenture Life Sciences. “We are committed to continuously expanding the scope of the service exchange to take advantage of the tremendous investments being made in innovative patient solutions.”

Companies currently providing technology solutions to the Accenture Intelligent Patient Service Exchange include AssistRx, Conga, Dell Boomi, Docusign and SpringCM.

When integrated with a company’s existing patient services program, the capabilities these companies provide can help life sciences companies deliver more predictable results and comprehensive patient support.

About Accenture

Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With more than 394,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.

EN
21/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Accenture Plc Class A

Accenture Plc: 1 director

A director at Accenture Plc sold 6,057 shares at 241.225USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : Shift to more favourable cycle to ease AI pressure on sector va...

While we do not deny the uncertainties and risks associated with artificial intelligence (pricing pressures, organisational change, etc.), we remain constructive on this issue, given the significant volume opportunities in prospect for the sector with the integration of agentic AI. Moreover, improving growth momentum in 2026 should reduce pressure on sector valuations (discount >30% vs Stoxx 600 vs a premium of 10% four years ago). On this basis, we have upgraded Bechtle (Outperform vs Neutral),...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : L’entrée dans un cycle plus favorable devrait réduire la pressi...

Sans nier les incertitudes et risques liés à l’IA (pressions tarifaires, changements organisationnels, etc.), nous restons constructifs sur cette thématique tant les opportunités de volumes autour de l’intégration de l’IA agentique sont importantes pour le secteur. D’autant plus que l’amélioration de la dynamique de croissance en 2026 devrait permettre de réduire la pression sur les valorisations du secteur (décote >30% vs Stoxx 600 contre une prime de 10% il y a 4 ans). Dans ce contexte, nous r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch